28443672|t|Heightened HIV antibody responses in postpartum women as exemplified by recent infection assays: implications for incidence estimates
28443672|a|Laboratory assays that identify recent HIV infections are important for assessing impacts of interventions aimed at reducing HIV incidence. Kinetics of HIV humoral responses can vary with inherent assay properties, and between HIV subtypes, populations and physiological states. They are important in determining mean duration of recent infection (MDRI) for antibody-based assays for detecting recent HIV infections. We determined MDRIs for BED-CEIA, LAg and BRAI assays for 101 seroconverting postpartum women, recruited in Harare in 1997- 2000 during the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) Trial, comparing them against published MDRIs estimated from seroconverting cases in the general population. We also compared MDRIs for women who seroconverted either during the first nine months, or at later stages, postpartum. At cut-offs (C) of 0.8 for BED, 1.5 for LAg and 40% for BRAI, estimated MDRIs for postpartum mothers, were 192, 104 and 144 days, 33%, 32-41% and 52% lower than published estimates of 287, 152-177 and 298 days, respectively, for clade C samples from general populations. Point estimates of MDRI values were 7 - 19% shorter for women who seroconverted in the first 9- months postpartum, compared with those seroconverting later. MDRI values for three HIV incidence biomarkers are longer in the general population than among postpartum women, particularly those who recently gave birth, consistent with heightened immunologic activation soon after birth. Our results provide a caution that MDRI may vary significantly between subjects in different physiological states.
28443672	0	10	Heightened	T080	C0442803
28443672	11	23	HIV antibody	T116,T129	C0019683
28443672	24	33	responses	T038	C0003261
28443672	37	53	postpartum women	T101	C0032804
28443672	79	95	infection assays	T059	C0005507
28443672	97	109	implications	T078	C1705535
28443672	114	123	incidence	T081	C0021149
28443672	124	133	estimates	T081	C0750572
28443672	134	151	Laboratory assays	T059	C0005507
28443672	157	165	identify	T080	C0205396
28443672	166	187	recent HIV infections	T047	C0019693
28443672	206	215	assessing	T058	C0184514
28443672	216	223	impacts	T080	C4049986
28443672	227	240	interventions	T058	C1273869
28443672	250	258	reducing	T080	C0392756
28443672	259	262	HIV	T047	C0019693
28443672	263	272	incidence	T081	C0021149
28443672	274	282	Kinetics	T070	C0022702
28443672	286	289	HIV	T047	C0019693
28443672	290	307	humoral responses	T043	C1155229
28443672	322	347	inherent assay properties	T080	C0871161
28443672	361	364	HIV	T005	C0019682
28443672	365	373	subtypes	T185	C0449560
28443672	375	386	populations	T098	C1257890
28443672	391	411	physiological states	T039	C0031843
28443672	452	460	duration	T079	C0449238
28443672	464	480	recent infection	T033	C2169571
28443672	482	486	MDRI	T033	C2169571
28443672	492	513	antibody-based assays	T059	C0005507
28443672	518	527	detecting	T061	C1511790
28443672	528	549	recent HIV infections	T047	C0019693
28443672	565	570	MDRIs	T033	C2169571
28443672	575	583	BED-CEIA	T059	C0086231
28443672	585	588	LAg	T059	C0086231
28443672	593	604	BRAI assays	T059	C0086231
28443672	613	627	seroconverting	T070	C4042908
28443672	628	644	postpartum women	T101	C0032804
28443672	659	665	Harare	UnknownType	C0681784
28443672	691	749	Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) Trial	T062	C0008976
28443672	751	760	comparing	T052	C1707455
28443672	774	783	published	T170	C0993637
28443672	784	789	MDRIs	T033	C2169571
28443672	790	799	estimated	T081	C0750572
28443672	805	819	seroconverting	T070	C4042908
28443672	820	825	cases	T077	C1706256
28443672	833	851	general population	T098	C0683971
28443672	861	869	compared	T052	C1707455
28443672	870	875	MDRIs	T033	C2169571
28443672	880	885	women	T098	C0043210
28443672	890	903	seroconverted	T070	C4042908
28443672	933	939	months	T079	C0439231
28443672	953	959	stages	T079	C0205390
28443672	961	971	postpartum	T079	C0086839
28443672	1000	1003	BED	T059	C0086231
28443672	1013	1016	LAg	T059	C0086231
28443672	1029	1033	BRAI	T059	C0086231
28443672	1035	1044	estimated	T081	C0750572
28443672	1045	1050	MDRIs	T033	C2169571
28443672	1055	1073	postpartum mothers	T101	C0032804
28443672	1097	1101	days	T079	C0439228
28443672	1123	1128	lower	T080	C0205251
28443672	1134	1153	published estimates	T170	C0993637
28443672	1178	1182	days	T079	C0439228
28443672	1202	1209	clade C	T185	C0449560
28443672	1210	1217	samples	T077	C2347026
28443672	1223	1242	general populations	T098	C0683971
28443672	1244	1259	Point estimates	T062	C1709586
28443672	1263	1267	MDRI	T033	C2169571
28443672	1268	1274	values	T170	C1285164
28443672	1288	1295	shorter	T080	C0205251
28443672	1300	1305	women	T098	C0043210
28443672	1310	1323	seroconverted	T070	C4042908
28443672	1340	1346	months	T079	C0439231
28443672	1347	1357	postpartum	T079	C0086839
28443672	1379	1393	seroconverting	T070	C4042908
28443672	1401	1405	MDRI	T033	C2169571
28443672	1406	1412	values	T170	C1285164
28443672	1423	1426	HIV	T047	C0019693
28443672	1427	1436	incidence	T081	C0021149
28443672	1437	1447	biomarkers	T201	C0005516
28443672	1452	1458	longer	T080	C0205250
28443672	1466	1484	general population	T098	C0683971
28443672	1496	1512	postpartum women	T101	C0032804
28443672	1551	1556	birth	T040	C0005615
28443672	1558	1573	consistent with	T078	C0332290
28443672	1574	1584	heightened	T080	C0442803
28443672	1585	1607	immunologic activation	T039	C1512670
28443672	1619	1624	birth	T040	C0005615
28443672	1630	1637	results	T169	C1274040
28443672	1661	1665	MDRI	T033	C2169571
28443672	1675	1688	significantly	T078	C0750502
28443672	1697	1705	subjects	T098	C2349001
28443672	1719	1739	physiological states	T039	C0031843